MORPHOLOGICAL FEATURES OF THE BLOOD VESSELS OF THE RENAL CORTEX IN EXPERIMENTAL METABOLIC SYNDROME

Authors

  • Sh. Q. Qosimova Tashkent State Medical University, Tashkent, Uzbekistan Author
  • I. A. Tilyabov Tashkent State Medical University, Tashkent, Uzbekistan Author

Keywords:

Keywords: metabolic syndrome, kidney, renal cortex, microcirculation, arterioles, peritubular capillaries, glomerulus, morphology, immunohistochemistry.

Abstract

Background. Metabolic syndrome (MS) affects roughly one in four adults worldwide and is an independent risk factor for chronic kidney disease. The vascular bed of the renal cortex – interlobular arteries, afferent and efferent arterioles, glomerular and peritubular capillaries – is one of the earliest targets of metabolic injury, yet its structural remodelling in MS remains insufficiently characterised.

Aim. To study the morphological features of the blood vessels of the renal cortex in experimental metabolic syndrome, to identify the structural changes developing in the microcirculatory bed, and to evaluate their relationship with the state of the nephron.

Materials and methods. Metabolic syndrome was induced in male outbred white rats (n = 20) by a high-fat, high-fructose diet for 12 weeks; intact animals (n = 20) served as controls. Paraffin sections of the renal cortex were stained with haematoxylin and eosin and periodic acid–Schiff (PAS), examined immunohistochemically for TGF-β1 and subjected to morphometric analysis.

Results. In the experimental group, the renal cortex showed marked plethora and stasis in the glomerular and peritubular capillaries and venules, dilatation of the tubular lumina with flattening, vacuolisation and partial desquamation of the epithelium, interstitial oedema, perivascular cellular infiltration and expansion of the perivascular connective tissue. Immunohistochemistry revealed intense immunoreactivity in the periglomerular, perivascular and peritubular interstitium and in the basolateral compartment of the tubular epithelium (score 2.4 ± 0.2 vs 0.8 ± 0.1 in controls). The wall-to-lumen ratio of afferent arterioles increased from 0.36 ± 0.02 to 0.64 ± 0.03, peritubular capillary density decreased by 22.0%, the glomerular tuft area increased by 19.8% and the height of the proximal tubular epithelium decreased by 26.8% (p < 0.01–0.001).

Conclusion. Experimental metabolic syndrome is accompanied by complex remodelling of the cortical vascular bed of the kidney, in which microcirculatory disturbances and perivascular changes accompany and probably precede tubulointerstitial injury. These changes can be regarded as early morphological markers of metabolic nephropathy.

References

1.Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the IDF Task Force on Epidemiology and Prevention; NHLBI; AHA; WHF; IAS; and IASO. Circulation. 2009;120(16):1640–1645.

2.Saklayen MG. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12.

3.Chen J, Muntner P, Hamm LL, Jones DW, Batuman V, Fonseca V, et al. The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med. 2004;140(3):167–174.

4.Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011;6(10):2364–2373.

5.Navaneethan SD, Schold JD, Kirwan JP, Arrigain S, Jolly SE, Poggio ED, et al. Metabolic syndrome, ESRD, and death in CKD. Clin J Am Soc Nephrol. 2013;8(6):945–952.

6.Alexander MP, Patel TV, Farag YMK, Florez A, Rennke HG, Singh AK. Kidney pathological changes in metabolic syndrome: a cross-sectional study. Am J Kidney Dis. 2009;53(5):751–759.

7.Wahba IM, Mak RH. Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease. Clin J Am Soc Nephrol. 2007;2(3):550–562.

8.Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019;15(6):367–385.

9.de Vries APJ, Ruggenenti P, Ruan XZ, Praga M, Cruzado JM, Bajema IM, et al. Fatty kidney: emerging role of ectopic lipid in obesity-related renal disease. Lancet Diabetes Endocrinol. 2014;2(5):417–426.

10.Kambham N, Markowitz GS, Valeri AM, Lin J, D’Agati VD. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001;59(4):1498–1509.

11.Helal I, Fick-Brosnahan GM, Reed-Gitomer B, Schrier RW. Glomerular hyperfiltration: definitions, mechanisms and clinical implications. Nat Rev Nephrol. 2012;8(5):293–300.

12.Bobulescu IA. Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens. 2010;19(4):393–402.

13.Kang DH, Kanellis J, Hugo C, Truong L, Anderson S, Kerjaschki D, et al. Role of the microvascular endothelium in progressive renal disease. J Am Soc Nephrol. 2002;13(3):806–816.

14.Chade AR. Renal vascular structure and rarefaction. Compr Physiol. 2013;3(2):817–831.

15.Panchal SK, Brown L. Rodent models for metabolic syndrome research. J Biomed Biotechnol. 2011;2011:351982.

16.Wong SK, Chin KY, Suhaimi FH, Fairus A, Ima-Nirwana S. Animal models of metabolic syndrome: a review. Nutr Metab (Lond). 2016;13:65.

17.Lerman LO, Kurtz TW, Touyz RM, Ellison DH, Chade AR, Crowley SD, et al. Animal models of hypertension: a scientific statement from the American Heart Association. Hypertension. 2019;73(6):e87–e120.

18.Nakagawa T, Hu H, Zharikov S, Tuttle KR, Short RA, Glushakova O, et al. A causal role for uric acid in fructose-induced metabolic syndrome. Am J Physiol Renal Physiol. 2006;290(3):F625–F631.

19.Sánchez-Lozada LG, Tapia E, Jiménez A, Bautista P, Cristóbal M, Nepomuceno T, et al. Fructose-induced metabolic syndrome is associated with glomerular hypertension and renal microvascular damage in rats. Am J Physiol Renal Physiol. 2007;292(1):F423–F429.

20.Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8(6):e1000412.

21.Meng XM, Nikolic-Paterson DJ, Lan HY. TGF-β: the master regulator of fibrosis. Nat Rev Nephrol. 2016;12(6):325–338.

22.Tervaert TWC, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–563.

Downloads

Published

2026-10-27